Sign In

Login

Password

Forgot Password ? Sign Up

Ritanserina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ritanserina" in Italian language version.

refsWebsite
Global rank Italian rank
21nih.gov
4th place
9th place
1oadoi.org
799th place
22nd place
1doi.org
2nd place
7th place

doi.org

dx.doi.org

nih.gov

ncbi.nlm.nih.gov

  • G. Nappi, G. Sandrini; F. Granella; L. Ruiz; G. Cerutti; F. Facchinetti; F. Blandini; GC. Manzoni, A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline., in Headache, vol. 30, n. 7, Jun 1990, pp. 439-44, PMID 2119355.
  • C. Idzikowski, FJ. Mills; R. Glennard, 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep., in Brain Res, vol. 378, n. 1, Jul 1986, pp. 164-8, PMID 3091188.
  • CA. Marsden, The pharmacology of new anxiolytics acting on 5-HT neurones., in Postgrad Med J, 66 Suppl 2, 1990, pp. S2-6, PMID 1975437.
  • B. Wagner, B. Schneider; B. Blöchl-Daum; W. Speiser; B. Brenner; HG. Eichler; K. Lechner; PA. Kyrle, Effect of ritanserin, a 5-hydroxytryptamine2-receptor antagonist, on platelet function and thrombin generation at the site of plug formation in vivo., in Clin Pharmacol Ther, vol. 48, n. 4, Oct 1990, pp. 419-23, PMID 2146058.
  • DJ. Stott, AR. Saniabadi; J. Hosie; GD. Lowe; SG. Ball, The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension., in Eur J Clin Pharmacol, vol. 35, n. 2, 1988, pp. 123-9, PMID 3142775.
  • NP. Chau, I. Pithois-Merli; J. Levenson; AC. Simon, Comparative haemodynamic effects of ketanserin and ritanserin in the proximal and distal upper limb circulations of hypertensive patients., in Eur J Clin Pharmacol, vol. 37, n. 3, 1989, pp. 215-20, PMID 2533074.
  • DL. Ceulemans, ML. Hoppenbrouwers; YG. Gelders; AJ. Reyntjens, The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam., in Pharmacopsychiatry, vol. 18, n. 5, Sep 1985, pp. 303-5, DOI:10.1055/s-2007-1017385, PMID 3931107.
  • GM. Bressa, S. Marini; S. Gregori, Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam., in Int J Clin Pharmacol Res, vol. 7, n. 2, 1987, pp. 111-9, PMID 3108171.
  • D. Bakish, YD. Lapierre; R. Weinstein; J. Klein; A. Wiens; B. Jones; E. Horn; M. Browne; D. Bourget; A. Blanchard, Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder., in J Clin Psychopharmacol, vol. 13, n. 6, Dec 1993, pp. 409-14, PMID 8120154.
  • M. Dahlitz, P. Wells; R. James; C. Idzikowski; JD. Parkes, Treatment of insomnia with ritanserin., in Lancet, vol. 336, n. 8711, Aug 1990, p. 379, PMID 1975361.
  • C. Idzikowski, PJ. Cowen; D. Nutt; FJ. Mills, The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan., in Psychopharmacology (Berl), vol. 93, n. 4, 1987, pp. 416-20, PMID 3124174.
  • T. Paiva, F. Arriaga; A. Wauquier; E. Lara; R. Largo; JN. Leitao, Effects of ritanserin on sleep disturbances of dysthymic patients., in Psychopharmacology (Berl), vol. 96, n. 3, 1988, pp. 395-9, PMID 3146774.
  • FA. Wiesel, AL. Nordström; L. Farde; B. Eriksson, An open clinical and biochemical study of ritanserin in acute patients with schizophrenia., in Psychopharmacology (Berl), vol. 114, n. 1, Feb 1994, pp. 31-8, PMID 7846205.
  • SJ. Duinkerke, PA. Botter; AA. Jansen; PA. van Dongen; AJ. van Haaften; AJ. Boom; JH. van Laarhoven; HL. Busard, Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial., in Br J Psychiatry, vol. 163, Oct 1993, pp. 451-5, PMID 7902766.
  • O. Vinar, J. Molcan; K. Náhunek; J. Svestka; M. Zapletálek, Ritanserin in schizophrenic patients., in Act Nerv Super (Praha), vol. 31, n. 2, Jun 1989, pp. 107-9, PMID 2508405.
  • A. Maertens de Noordhout, PJ. Delwaide, Open pilot trial of ritanserin in parkinsonism., in Clin Neuropharmacol, vol. 9, n. 5, 1986, pp. 480-4, PMID 3094935.
  • J. Henderson, C. Yiannikas; JS. Graham, Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease., in Clin Exp Neurol, vol. 29, 1992, pp. 277-82, PMID 1343870.
  • F. Estevez, S. Parrillo; M. Giusti; JM. Monti, Single-dose ritanserin and alcohol in healthy volunteers: a placebo-controlled trial., in Alcohol, vol. 12, n. 6, pp. 541-5, PMID 8590616.
  • JM. Monti, P. Alterwain; F. Estévez; F. Alvariño; M. Giusti; S. Olivera; P. Labraga, The effects of ritanserin on mood and sleep in abstinent alcoholic patients., in Sleep, vol. 16, n. 7, Oct 1993, pp. 647-54, PMID 8290859.
  • CA. Naranjo, CX. Poulos; KL. Lanctôt; KE. Bremner; M. Kwok; M. Umana, Ritanserin, a central 5-HT2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects., in Addiction, vol. 90, n. 7, Jul 1995, pp. 893-905, PMID 7663312.
  • BA. Johnson, DR. Jasinski; GP. Galloway; H. Kranzler; R. Weinreib; RF. Anton; BJ. Mason; MJ. Bohn; HM. Pettinati; R. Rawson; C. Clyde, Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group., in Psychopharmacology (Berl), vol. 128, n. 2, Nov 1996, pp. 206-15, PMID 8956382.

oadoi.org